Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03841110
Title FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics
Indications

Advanced Solid Tumor

lymphoma

Therapies

FT500 + Pembrolizumab

Atezolizumab + FT500

FT500 + Nivolumab

FT500

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.